U.S.A.'s interesting latest news

Y

Building Manager Open 12/10/2018 to 12/21/2018 Department: Public Buildings Service Job Location: New York, New York Contract Specialist Open 12/10/2018 to 12/19/2018 Department: Public Buildings Service Job Location: Multiple Locations Property Disposal Officer Open 12/11/2018 to 12/20/2018 Department: Federal Acquisition Service Job Location: Fort Worth, Texas Program Analyst Open 12/10/2018 to 12/24/2018 Department: Office of the Chief Financial Officer Job Location: Washington DC, District of Columbia Criminal Investigator Open 12/11/2018 to 12/17/2018 Department: Office of Inspector General Job Location: Multiple Locations Supervisory Contract Specialist Open 12/11/2018 to 12/24/2018 Department: Office of Administrative Services Job Location: Washington DC, District of Columbia Program Analyst Open 12/11/2018 to 12/26/2018 Department: Technology Transformation Service Job Location: Multiple Locations Congressional Liaison Specialist Open 12/12/2018 to 12/26/2018 Department: Office of Congressional and Intergovernmental Affairs Job Location: Washington DC, District of Columbia Financial Management Analyst Open 12/12/2018 to 12/27/2018 Department: Office of the Chief Financial Officer Job Location: Multiple Locations Smart Buildings Program Specialist Open 12/12/2018 to 12/26/2018 Department: Public Buildings Service Job Location: District of Columbia, District of Columbia Smart Buildings Program Specialist Open 12/12/2018 to 12/26/2018 Department: Public Buildings Service Job Location: District of Columbia, District of Columbia Realty Specialist Open 12/12/2018 to 12/21/2018 Department: Public Buildings Service Job Location: Multiple Locations Interdisciplinary Architect/Engineer Open 12/17/2018 to 01/04/2019 Department: Public Buildings Service Job Location: Kansas City, Missouri Program Analyst Open 12/12/2018 to 12/18/2018 Department: Technology Transformation Service Job Location: Washington DC, District of Columbia Procurement Technician Open 12/13/2018 to 12/24/2018 Department: Public Buildings Service Job Location: Tucson, Arizona Procurement Technician Open 12/13/2018 to 12/24/2018 Department: Public Buildings Service Job Location: Tucson, Arizona Procurement Analyst Open 12/13/2018 to 01/04/2019 Department: Public Buildings Service Job Location: Philadelphia, Pennsylvania Contract Specialist Open 12/13/2018 to 01/04/2019 Department: Public Buildings Service Job Location: Philadelphia, Pennsylvania Contract Specialist Open 12/14/2018 to 12/26/2018 Department: Federal Acquisition Service Job Location: Stuttgart, Germany Supervisory Contract Specialist Open 12/14/2018 to 12/26/2018 Department: Federal Acquisition Service Job Location: Philadelphia, Pennsylvania Smart Buildings Program Specialist Open 12/12/2018 to 12/26/2018 Department: Public Buildings Service Job Location: District of Columbia, District of Columbia Realty Specialist Open 12/12/2018 to 12/21/2018 Department: Public Buildings Service Job Location: Multiple Locations Procurement Technician Open 12/13/2018 to 12/24/2018 Department: Public Buildings Service Job Location: Tucson, Arizona Realty Specialist Open 12/14/2018 to 12/28/2018 Department: Public Buildings Service Job Location: New York, New York Small Business Specialist Open 12/13/2018 to 12/27/2018 Department: Office of Small Business Utilization Job Location: Washington DC, District of Columbia Business Operations Director Open 12/14/2018 to 12/20/2018 Department: Technology Transformation Service Job Location: District of Columbia, District of Columbia IT Specialist (INFOSEC) Open 12/14/2018 to 12/27/2018 Department: Office of the Chief Information Officer Job Location: Location Negotiable After Selection, United States Project Information Systems Coordinator Open 12/17/2018 to 12/31/2018 Department: Public Buildings Service Job Location: Washington DC, District of Columbia FTC Approves Teva Petition to Reopen and Modify Decision and Order in Case Involving Watson Pharmaceuticals Inc.’s Acquisition of Actavis Inc. The Federal Trade Commission has approved an application by Teva to reopen and modify its decision and order in connection with the 2012 merger of Watson Pharmaceuticals, Inc. and Actavis Inc. The Commission had alleged that the merger might lessen future competition for a number of generic drugs, including the generic version of the abuse-resistant opioid painkiller sold under the brand name Embeda. The 2012 decision and order required Watson and Actavis to supply Embeda to Pfizer Inc. for a period not to exceed four years after Pfizer’s relaunch of Embeda, which occurred in January 2015. The decision and order also required Watson and Actavis to assist in the transfer of technology for manufacturing Embeda to Pfizer or a third party. In 2016, Teva acquired Actavis’s rights and obligations under the Embeda supply agreement. Teva seeks to extend, at Pfizer’s request, the Embeda supply agreement for an additional period because Pfizer has not yet completed the technology transfer for Embeda manufacturing to a third party. Without Teva’s supply of Embeda, Pfizer will be unable to supply patients with Embeda after December 2018. The Commission vote to approve the application was 4-0-1, with Commissioner Christine S. Wilson recused. (FTC File No. 1210132; the staff contact is Elizabeth Piotrowski, Bureau of Competition, 202-326-2623.) Administrative Law Judge Upholds FTC’s Complaint Allegations that Merger of Major Titanium Dioxide Companies would have Harmed Competition In an Initial Decision announced today, Chief Administrative Law Judge D. Michael Chappell upheld allegations in a Federal Trade Commission complaint challenging the merger of Tronox Limited and Cristal, two top suppliers of chloride process titanium dioxide (“TiO2”), a white pigment used in a wide variety of products, including paint, industrial coatings, plastic, and paper. “The evidence proves that the planned Acquisition may substantially lessen competition in the relevant market for the sale of chloride TiO2 in North America in violation of Section 7 of the Clayton Act and Section 5 of the FTC Act,” Judge Chappell wrote in the decision. He concluded that the planned Acquisition would create a highly concentrated market and increase the likelihood of coordinated conduct among the remaining firms. “Respondents have failed to rebut this proof, including by failing to demonstrate that entry or expansion would be timely, likely, and sufficient to counteract the likely anticompetitive effects of the Acquisition, or to demonstrate cognizable synergies or efficiencies that might justify the likely anticompetitive effects of the Acquisition,” Judge Chappell wrote. An order Judge Chappell included with the Dec. 7, 2018 Initial Decision would require the respondents to terminate the Proposed Acquisition Agreement and cease taking any direct or indirect actions to consummate it; to return all confidential information to each other; and to certify final compliance within 15 days of the order becoming final. According to the FTC’s Administrative Complaint, Tronox Limited’s proposed acquisition of competitor Cristal, for $1.67 billion and a 24 percent stake in the combined entity, would violate the antitrust laws by significantly reducing competition in the North American market (comprised of the United States and Canada) for chloride process titanium dioxide. The FTC alleged that the acquisition, if consummated, would increase the risk of coordinated action among the remaining competitors, and increase the risk of future anticompetitive output reductions by Tronox. The Appeals Process. Because the Federal Trade Commission has sought preliminary relief to prevent consummation of the proposed acquisition in federal court, Commission Rule 3.52(a) provides that the Judge’s Initial Decision is subject to automatic review by the full Commission. On September 12, 2018, the United States District Court for the District of Columbia issued a Memorandum Opinion and Order granting the Commission’s Motion For Preliminary Injunction. ------------------- MedWatch - The FDA Safety Information and Adverse Event Reporting Program A new MedWatch Safety Alert recall: Dyural-40 and Dyural-80 Convenience Kits Containing Recalled Sodium Chloride Injection by Enovachem Pharmaceuticals:Recall - Due to Latex Hazard was just added to the FDA Recalls webpage.   You can read the complete recall alert at: https://www.fda.gov/Safety/Recalls/ucm628712.htm Enovachem Pharmaceuticals Issues Voluntary Nationwide Recall of Dyural-40 and Dyural-80 Convenience Kits Containing Recalled Sodium Chloride Injection, USP, 0.9% Due to Latex Hazard Torrance, CA, Asclemed USA Inc is voluntarily recalling 20 lots of Dyural-40 and 61 lots of Dyural-80, to the user level. The products include recalled Sodium Chloride, USP, 0.9% manufactured by Fresenius Kabi, which has been recalled due to product labeling incorrectly stating stoppers do not contain latex. For the population most at risk, those with a severe allergic reaction to latex, there is probability of an anaphylactic reaction, and this could result in hospitalization or death. To date, Asclemed USA Inc has not received any reports of adverse events related to this recall. The products are Dyural-40 convenience kits packaged in plastic trays and Dyural-80 convenience kits packaged in plastic trays, containing Sodium Chloride, USP, 0.9% by Fresenius Kabi. Spokane Produce Voluntarily Recalls Northwest Cuisine Creations and Fresh&Local Sandwiches and Green Leaf Lettuce Filets Spokane Produce Inc. of Spokane, WA initiates a voluntary recall of sandwiches containing green leaf lettuce and foodservice lettuce filets following notice of a produce industry ingredient recall by Adam Bros. Farming Inc. Sandwich products bearing the Northwest Cuisine Creations and Fresh&Local labels. These prod- ucts are recalled because they may be contaminated with Escherichia coli O157:H7 bacteria (E. Coli O157:H7). E. coli O157:H7 causes a diarrheal illness often with bloody stools. Although most healthy adults can recover completely within a week, some people can develop a form of kidney failure called Hemolytic Uremic Syndrome (HUS). HUS is most likely to occur in young children and the elderly. The condition can lead to serious kidney damage and even death. Tips to Avoid Gift Card Scams Gift cards are a great problem solver for those who struggle finding gifts during the holidays. But scammers sometimes use them as a way to steal your money. In some cases, you might get a call from someone pretending to be from the IRS, posing as a family member, or another new scheme demanding a gift card payment. They will urge or even threaten you to send them money right away. Don't fall for it!